For Andrew Witty, it's a question of redefining the unwritten contract that major drug companies have with society. For critics of big pharma, it's about addressing widely felt concerns about an industry that has often seemed heartless. Either way, the changes proposed by the chief executive of GlaxoSmithKline goes to the core of one of the most toxic debates of our time.